ArticleHealth economics review2026
Economic burden of blindness and moderate to severe vision impairment in Slovenia.
Article in Health economics review, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundBlindness and moderate to severe vision impairment (MSVI) represent a substantial health and economic burden. This study aimed to provide the first population-level estimates of healthcare expenditures and sickness absenteeism costs associated with blindness and MSVI in Slovenia.
methodsIn this economic evaluation study, the analysis of direct healthcare costs from the third-party payer’s perspective was based on population-level reimbursement claims data while indirect costs due to absenteeism were estimated using the human capital method. Hospitalized patients with diagnoses H54.0-H54.3 (according to the International Classification of Diseases, 10th revision) or users of assistive aids for individuals with blindness and MSVI who were still alive in 2022 were included in the study. For this target population of patients, the burden of blindness and MSVI was estimated by considering eye diseases and other health conditions strongly associated with vision-impartment (injuries, depression and anxiety).
resultsAmong 4,153 blind and MSVI patients included in this study, 256 (6.2%) were younger than 18 years, and 3,161 (76.1%) were aged 60 years or older; 2,542 (61.2%) were female. Direct healthcare costs in 2022 amounted to €5,539,173 (€1,334 per patient). Only 3.3% of these costs were related to people under 18 years of age. A total of 80.3% of the costs were related to eye diseases, 17.1% to injuries, and 2.5% to depression and anxiety disorders. The largest share of direct healthcare costs was attributable to outpatient care (45.1%), followed by drugs and assistive aids for individuals with blindness and MSVI (34.5%), and hospitalizations (20.4%). Absenteeism costs ranged between €298,885 and €342,192 (€5,978–€6,844 per absentee).
conclusionsIn Slovenia, vision loss represents a substantial economic burden, which is expected to increase due to population aging and growth. To mitigate the increasing burden of vision loss, effective strategies for prevention, early detection, optimal treatment, and long-term management of eye diseases are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.